期刊
CURRENT OPINION IN VIROLOGY
卷 38, 期 -, 页码 1-9出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2019.03.004
关键词
-
类别
资金
- National Health and Medical Research Council (NHMRC) of Australia
- National Institutes of Health [UM lAI126611]
- American Foundation for AIDS Research [amfAR 109226-58-RGRL]
Latently infected cells that persist in HIV-infected individuals on antiretroviral therapy (ART) are a major barrier to cure. One strategy to eliminate latency is by activating viral transcription, commonly called latency reversal. Several small non-randomised clinical trials of latency reversing agents (LRAs) in HIV-infected individuals on ART increased viral production, but disappointingly did not reduce the number of latently infected cells or delay time to viral rebound following cessation of ART. More recent approaches aimed at reversing latency include compounds that both activate virus and also modulate immunity to enhance clearance of infected cells. These immunomodulatory LRAs include toll-like receptor agonists, immune checkpoint inhibitors and some cytokines. Here, we provide a brief review of the rationale for transcription-activating and immunomodulatory LRAs, discuss recent clinical trials and some suggestions for combination approaches and research priorities for the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据